Alvotech And Fuji Further Expand Biosimilars Partnership
Japanese Commercialization Alliance Now Covers Six Alvotech Candidates
Executive Summary
Alvotech and Fuji Pharma have extended their strategic alliance for the commercialization of Alvotech biosimilars in Japan, adding a further early-stage candidate to the list of products covered by the deal that now encompasses six biosimilars.
You may also be interested in...
Alvotech’s Japanese Ustekinumab Nod Is ‘First For Global Markets’
Following the formation of their partnership nearly five years ago, Alvotech and Fuji have together welcomed approval in Japan for Alvotech’s biosimilar to Stelara (ustekinumab).
Asia Deal Watch: Huadong Licenses Two Cancer ADCs From Heidelberg Pharma
German firm’s antibody-drug conjugates use amanitin payload. Plus deals involving Sanwa Kagaku/Crinetics, Takeda/Code Bio, Taro/Alchemee, Mankind/Dr. Reddy’s and more.
Alvotech Humira Settlement Sets Up Interchangeable Adalimumab Showdown
Alvotech and AbbVie have settled all of their legal disputes over Alvotech’s AVT02 biosimilar rival to Humira. With Alvotech seeking a coveted interchangeability designation for its higher-strength adalimumab, the firm’s US entry date provided by the settlement matches that of Boehringer Ingelheim’s interchangeable Cyltezo lower-strength adalimumab biosimilar.